1
|
Ultimo S, Martelli AM, Zauli G, Vitale M, Calin GA, Neri LM. Roles and clinical implications of microRNAs in acute lymphoblastic leukemia. J Cell Physiol 2018; 233:5642-5654. [DOI: 10.1002/jcp.26290] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Accepted: 11/14/2017] [Indexed: 12/17/2022]
Affiliation(s)
- Simona Ultimo
- Department of Morphology, Surgery and Experimental MedicineUniversity of FerraraFerraraItaly
| | - Alberto M. Martelli
- Department of Biomedical and Neuromotor SciencesUniversity of BolognaBolognaItaly
| | - Giorgio Zauli
- Department of Morphology, Surgery and Experimental MedicineUniversity of FerraraFerraraItaly
| | - Marco Vitale
- Department of Medicine and Surgery, Sport and Exercise Medicine Centre (SEM)University of ParmaParmaItaly
- CoreLabHospital‐University of ParmaParmaItaly
| | - George A. Calin
- Departments of Experimental Therapeutics and LeukemiaThe University of Texas MD Anderson Cancer CenterHoustonTexas
- Center for RNA Interference and Non‐Coding RNAsThe University of Texas MD Anderson Cancer CenterHoustonTexas
| | - Luca M. Neri
- Department of Morphology, Surgery and Experimental MedicineUniversity of FerraraFerraraItaly
| |
Collapse
|
2
|
Abstract
B-cell chronic lymphocytic leukemia (CLL) is the most common adult human leukemia. Although, the molecular alterations leading to CLL onset and progression are still under investigation (specifically, the interplay and exact role of oncogenes and tumor suppressors in CLL pathogenesis). MicroRNAs are small non-coding RNAs that regulate gene expression and are expressed in a tissue specific manner. Deregulation of microRNAs can alter expression levels of genes involved in the development and/or progression of tumors. In CLL, microRNAs can function as oncogenes or tumor suppressors. Here, we review the most recent findings on the role of microRNAs in the onset/progression of CLL, and how this knowledge can be used to identify new biomarkers and targets to treat this leukemia.
Collapse
Affiliation(s)
- Veronica Balatti
- Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Wexner Medical Center, The Ohio State University, Columbus, OH, USA
| | - Mario Acunzo
- Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Wexner Medical Center, The Ohio State University, Columbus, OH, USA
| | - Yuri Pekarky
- Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Wexner Medical Center, The Ohio State University, Columbus, OH, USA
| | - Carlo M Croce
- Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Wexner Medical Center, The Ohio State University, Columbus, OH, USA
| |
Collapse
|
3
|
Sharifi M, Salehi R, Gheisari Y, Kazemi M. Inhibition of microRNA miR-92a induces apoptosis and inhibits cell proliferation in human acute promyelocytic leukemia through modulation of p63 expression. Mol Biol Rep 2014; 41:2799-808. [PMID: 24481878 DOI: 10.1007/s11033-014-3134-5] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2013] [Accepted: 01/11/2014] [Indexed: 12/15/2022]
Abstract
MicroRNAs (miRNAs) are endogenous non-coding RNAs, 19-25 nucleotides in length involved in post-transcriptional regulation of gene expression of great majority of the human protein coding genes. Different aspects of cellular activities like cell growth, proliferation, and differentiation are regulated by miRNAs through their interaction with particular RNA species. In many tumors up or down-regulation of different miRNAs has been reported. Human miR-17-92 gene cluster is located on 13q31.3, rooming several miRNAs including miR-17-5p, miR-17-3p, miR-18, miR-19a, miR-20a and miR-92a. Amplification or overexpression of this cluster has been reported in acute myeloid leukemia, acute lymphoblastic leukemia and several other cancer types. Here, we performed inhibition of miR-92a in an acute promyelocytic leukemia (APL) cell line (HL-60) using locked nucleic acid (LNA) antagomir. In different time points after LNA-anti-miR92a transfection, MTT assay and annexin/propidium iodide staining were performed. These assessments indicate that miR-92a inhibition can extensively decrease the viability of these cells which is mainly due to induction of apoptosis. Western blot analysis of p63 protein also revealed that miR-92a inhibition resulted in p63 expression, hence activation of cellular pathways which are normally controlled by p63 protein are retrieved. These findings could open up a path to the miRNAs based therapeutic approach for treatment of APL.
Collapse
Affiliation(s)
- Mohammadreza Sharifi
- Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, 81744-176, Isfahan, Iran
| | | | | | | |
Collapse
|
4
|
Sharifi M, Salehi R, Gheisari Y, Kazemi M. WITHDRAWN: Inhibition of MicroRNA miR-92a Inhibits Cell Proliferation in Human Acute Promyelocytic Leukemia. Turk J Haematol 2013; 30:157-62. [PMID: 24385779 PMCID: PMC3878471 DOI: 10.4274/tjh.2012.0171] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2012] [Accepted: 12/31/2012] [Indexed: 12/13/2022] Open
Abstract
This article has been withdrawn due to the fact that it is published in three different journals.
Collapse
Affiliation(s)
- Mohammadreza Sharifi
- Mohammadreza Sharifi, Rasoul Salehi, Yousof Gheisari, Mohammad Kazemi Pediatrics Inherited Diseases Research Center & Department Of Genetics And Molecular Biology, School Of Medicine, Isfahan University Of Medical Sciences, Isfhan, Iran
| | - Rasoul Salehi
- Mohammadreza Sharifi, Rasoul Salehi, Yousof Gheisari, Mohammad Kazemi Pediatrics Inherited Diseases Research Center & Department Of Genetics And Molecular Biology, School Of Medicine, Isfahan University Of Medical Sciences, Isfhan, Iran
| | - Yousof Gheisari
- Mohammadreza Sharifi, Rasoul Salehi, Yousof Gheisari, Mohammad Kazemi Pediatrics Inherited Diseases Research Center & Department Of Genetics And Molecular Biology, School Of Medicine, Isfahan University Of Medical Sciences, Isfhan, Iran
| | - Mohammad Kazemi
- Mohammadreza Sharifi, Rasoul Salehi, Yousof Gheisari, Mohammad Kazemi Pediatrics Inherited Diseases Research Center & Department Of Genetics And Molecular Biology, School Of Medicine, Isfahan University Of Medical Sciences, Isfhan, Iran
| |
Collapse
|
5
|
Abstract
MicroRNAs are a class of small non-coding RNAs regulating gene expression at posttranscriptional level. Their target genes include numerous regulators of cell cycle, cell proliferation as well as apoptosis. Therefore, they are implicated in the initiation and progression of cancer, tissue invasion and metastasis formation as well. MicroRNA profiles supply much information about both the origin and the differentiation state of tumours. MicroRNAs also have a key role during haemopoiesis. An altered expression level of those have often been observed in different types of leukemia. There are successful attempts to apply microRNAs in the diagnosis and prognosis of acute lymphoblastic leukemia and acute myeloid leukemia. Measurement of the expression levels may help to predict the success of treatment with different kinds of chemotherapeutic drugs. MicroRNAs are also regarded as promising therapeutic targets, and can contribute to a more personalized therapeutic approach in haemato-oncologic patients.
Collapse
Affiliation(s)
- Zsuzsanna Gaál
- Debreceni Egyetem, Általános Orvostudományi Kar, Orvos- és Egészségtudományi Centrum Gyermekgyógyászati Intézet
| | | |
Collapse
|
6
|
Abstract
B-cell chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. CLL occurs in two forms, aggressive and indolent. Aggressive CLL is characterized by high ZAP-70 expression and unmutated IgH VH; indolent CLL shows low ZAP-70 expression and mutated IgH VH. We recently found that miR-29 is upregulated in indolent human B-CLL, compared to aggressive B-CLL and normal CD19+ B-cells. To determine the role of miR-29 in CLL, we generated transgenic mice overexpressing miR-29 in mouse B-cells. Recently we reported that miR-29 transgenic mice develop indolent CLL phenotype. Interestingly, our previous findings suggest that miR-29 targets expression of TCL1, a critical oncogene in aggressive CLL, indicating that miR-29 might function as a tumor suppressor in CLL. Here we discuss these results and provide additional insights into function of miR-29 in CLL.
Collapse
Affiliation(s)
- Yuri Pekarsky
- Human Cancer Genetics Program and Department of Molecular Virology, Immunology and Medical Genetics, OSU School of Medicine, Ohio State University, Columbus, Ohio.
| | | |
Collapse
|
7
|
Borze I, Guled M, Musse S, Raunio A, Elonen E, Saarinen-Pihkala U, Karjalainen-Lindsberg ML, Lahti L, Knuutila S. MicroRNA microarrays on archive bone marrow core biopsies of leukemias—Method validation. Leuk Res 2011; 35:188-95. [DOI: 10.1016/j.leukres.2010.08.005] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2010] [Revised: 08/12/2010] [Accepted: 08/12/2010] [Indexed: 01/25/2023]
|
8
|
Focused on Frontier Sciences and Dedicated to Academic Exchanges-<I>Science China: Life Sciences</I> in 2009 at a New Beginning. PROG BIOCHEM BIOPHYS 2011. [DOI: 10.3724/sp.j.1206.2010.00555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
9
|
The Recent Progress of Non-coding RNA and RNomics. PROG BIOCHEM BIOPHYS 2010. [DOI: 10.3724/sp.j.1206.2010.00475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Research frontiers highlighted in Science China Life Sciences in 2009. CHINESE SCIENCE BULLETIN-CHINESE 2010. [DOI: 10.1007/s11434-010-4229-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A, Sato A, Kondo S, Kojima T, Deguchi T, Ito M. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 2010; 285:19076-84. [PMID: 20406806 DOI: 10.1074/jbc.m109.079525] [Citation(s) in RCA: 156] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
MicroRNAs are involved in cancer pathogenesis and act as tumor suppressors or oncogenes. It has been recently reported that miR-148a expression is down-regulated in several types of cancer. The functional roles and target genes of miR-148a in prostate cancer, however, remain unknown. In this report, we showed that miR-148a expression levels were lower in PC3 and DU145 hormone-refractory prostate cancer cells in comparison to PrEC normal human prostate epithelial cells and LNCaP hormone-sensitive prostate cancer cells. Transfection with miR-148a precursor inhibited cell growth, and cell migration and invasion, and increased the sensitivity to anti-cancer drug paclitaxel in PC3 cells. Computer-aided algorithms predicted mitogen- and stress-activated protein kinase, MSK1, as a potential target of miR-148a. Indeed, miR-148a overexpression decreased expression of MSK1. Using luciferase reporter assays, we identified MSK1 as a direct target of miR-148a. Suppression of MSK1 expression by siRNA, however, showed little or no effects on malignant phenotypes of PC3 cells. In PC3PR cells, a paclitaxel-resistant cell line established from PC3 cells, miR-148a inhibited cell growth, and cell migration and invasion, and also attenuated the resistance to paclitaxel. MiR-148a reduced MSK1 expression by directly targeting its 3'-UTR in PC3PR cells. Furthermore, MSK1 knockdown reduced paclitaxel-resistance of PC3PR cells, indicating that miR-148a attenuates paclitaxel-resistance of hormone-refractory, drug-resistant PC3PR cells in part by regulating MSK1 expression. Our findings suggest that miR-148a plays multiple roles as a tumor suppressor and can be a promising therapeutic target for hormone-refractory prostate cancer especially for drug-resistant prostate cancer.
Collapse
Affiliation(s)
- Yasunori Fujita
- Department of Longevity and Aging Research, Gifu International Institute of Biotechnology, Kakamigahara, Gifu 504-0838, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|